Fosaprepitant - Merck & Co

Drug Profile

Fosaprepitant - Merck & Co

Alternative Names: Emend For Injection; Emend IV; Fosaprepitant dimeglumine; IVEmend; MK-0517; MK-517; ONO-7847; Proemend

Latest Information Update: 04 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Developer Merck & Co; Ono Pharmaceutical
  • Class Antiemetics; Morpholines; Small molecules
  • Mechanism of Action Neurokinin 1 receptor antagonists; Substance P inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting
  • No development reported Postoperative nausea and vomiting

Most Recent Events

  • 23 Mar 2018 The Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion for Chemotherapy induced nausea and vomiting (In infants, In children, In adolescents) in European Union
  • 22 Mar 2018 Preregistration for Chemotherapy induced nausea and vomiting (In children, In infants, In adolescents) in European Union before March 2018
  • 16 Feb 2018 Ono Pharmaceutical initiates a phase III trial in Chemotherapy induced nausea and vomiting (In infants, In children, In adolescents) in Japan (EudraCT2018-000663-80)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top